Taking stock of the drug industry, from the lab to the medicine chestApril 29, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Amid FDA chaos, approval of a rare disease drug gets delayed — again "In my opinion, this is because of the chaos and lack of resources," said a former FDA official familiar with the matter. By Ed Silverman STAT+ | The end of compounded GLP-1 copies leaves many patients in a 'lose-lose' position Thousands face uncertainty as compounded GLP-1s disappear, struggling to afford care and navigate sudden changes in obesity and diabetes treatment. By Katie Palmer and Elaine Chen STAT+ | Gilead will pay $202 million to settle charges of paying kickbacks to docs for boosting HIV drug sales The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV medicines. By Ed Silverman Adobe STAT+ | Novo Nordisk strikes telehealth deals for obesity drug, following Eli Lilly The move could help Novo Nordisk expand the direct-to-consumer market for Wegovy, as it also seeks to fend off competition from compounders. By Elaine Chen STAT+ | How Marty Makary's FDA is embracing a more skeptical view of vaccines FDA vaccine oversight is shifting under RFK Jr. and Marty Makary, with increased scrutiny, mixed messaging, and growing concerns among health experts. By Lizzy Lawrence More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments